January 11, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, announced the enrollment of the first patient in Part 2 of the IMPROVE-DiCE Phase 2 clinical trial of ninerafaxstat in patients with heart failure with preserved ejection fraction (HFpEF). Ninerafaxstat is currently in Phase 2 clinical development in three indications: non-obstructive hypertrophic cardiomyopathy (nHCM), stable angina, and HFpEF.
“HFpEF is now the most common form of heart failure, affecting over 3 million adults in the U.S., reflecting the aging of the general population and the global epidemic of type 2 diabetes and obesity,” said Jai Patel, MRCP (U.K.), chief medical officer at Imbria. “Ninerafaxstat is designed to reduce the over reliance on fatty acids as a fuel choice in the heart that underlies impaired energy generation in HFpEF and leads to debilitating symptoms such as breathlessness, fatigue and reduced exercise capacity for which there are currently limited treatment options.”
“Part 2 of the IMPROVE-DiCE trial will assess the effects of ninerafaxstat on cardiac energetics, heart failure symptom burden and functional capacity in patients with HFpEF. We look forward to sharing initial results from this trial in 2023 as well as report on the results of our two other Phase 2 trials in nHCM and stable angina,” Dr. Patel concluded.
Anne Prener, M.D., Ph.D., president and chief executive officer of Imbria, commented, “Initiation of patient enrollment in this Phase 2 clinical trial, assessing the safety and efficacy of ninerafaxstat, in the underserved patient population of HFpEF is yet another important step in the development of ninerafaxstat, as we continue to evaluate its potential to make a meaningful impact on major unmet needs in HFpEF, stable angina, and nHCM.”
For more information: www.imbria.com
Related content:
Penn Study Identifies New Prognostic Biomarker for Heart Failure
April 22, 2024 
